Hikma Pharmaceuticals PLC Annual report 2010 notes to tHe ConsoLIdAted FInAnCIALstAtements Continued 17. deFerred tAx The following are the major deferred tax liabilities and assets recognised by the Group and movements thereon during the current and prior reporting years.
The following is the analysis of the deferred tax balances after offset for financial reporting purposes: 2010 2009 $000 $000 deferred tax liabilities 12,404 11,734 deferred tax assets 23,288 18,793 10,884 7,059 No deferred tax asset has been recognised on temporary differences totalling USD 56,690,000 2009: USD 3,873,000 due to the unpredictability ofthe related future profit streams.
The significant increase during 2010 relates mainly to the increased eligibility of certain intra-group sales to be recognised as temporary differences.
Of these temporary differences, USD 6,194,000 relates to losses which may be carried forward for two years before expiry and USD 3,374,000 relate to losses which may be carried forward for four years before expiry.
No deferred tax liability is recognised on temporary differences of USD 36 million 2009: USD 30 million relating to the unremitted earnings ofoverseas subsidiaries as the Group is able to control the timing of the reversal of these temporary differences and it is probable that they will not reverse in the foreseeable future.
